Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Lancet (London, England)·2024

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Leukemia·2023

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

The Lancet. Haematology·2021

Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).

The Lancet. Haematology·2021

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

The Lancet. Oncology·2021

Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.

British journal of haematology·2021

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

The Patient Who Could Not Die.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies.

Cureus·2026

Clinical Outcomes of Rh(D)-Incompatible Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Centre Retrospective Case Series with a Narrative Literature Review.

Journal of blood medicine·2026

CD56-Positive Acute Myeloid Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: A case report and narrative review.

Pakistan journal of medical sciences·2026

Prognostic Factors Associated With Mortality in Adult Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis.

Cureus·2026

Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX.

Journal of the American College of Cardiology·2026

A multicenter prospective observational cohort study to improve diagnostic yield and clinical management of persons with a Bleeding Disorder of Unknown Cause (BDUC-iN study protocol).

Research and practice in thrombosis and haemostasis·2026

Related Experiment Videos

Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

Related Concept Videos

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

The Patient Who Could Not Die.

Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies.

Clinical Outcomes of Rh(D)-Incompatible Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Centre Retrospective Case Series with a Narrative Literature Review.

CD56-Positive Acute Myeloid Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: A case report and narrative review.

Prognostic Factors Associated With Mortality in Adult Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis.

Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX.

A multicenter prospective observational cohort study to improve diagnostic yield and clinical management of persons with a Bleeding Disorder of Unknown Cause (BDUC-iN study protocol).

Related Experiment Videos

Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

Related Concept Videos

Related Articles